CMS launches payment model for state Medicaid programs to purchase drugs at most-favored-nation pricing
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned with those paid in other countries, known as most-favored-nation pricing. The program, called the GENErating cost Reductions fOr U.S. (GENEROUS) Medicaid Model, will be coordinated by the CMS Innovation Center. CMS said it will issue a request for applications later this fall for drug manufacturers interested in participating in the model. The agency will also seek letters of intent from interested state Medicaid agencies.
Related News Articles
Headline
The Health Resources and Services Administration has awarded approximately $7 million in grants to seven recipients in the fiscal year 2026 cohort of its Rural…
Headline
The AHA Sept. 23 submitted comments on the Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act). The…
Headline
In part two of this special three-part Advancing Health podcast series, hear how leaders are creating new pathways into the workforce, investing in training,…
Headline
The Centers for Medicare & Medicaid Services has released preliminary calendar year 2027 Medicare clinical laboratory fee schedule payment rates. The rates…
Headline
Corey Casper, M.D., senior vice president and chief research officer at Banner Health, and professor of clinical translational science at the University of…
Headline
The AHA commented Sept. 21 on the Centers for Medicare & Medicaid Services’ proposed rule to implement the changes to Medicaid provider tax policies that…